Wall Street analysts forecast that Eagle Pharmaceuticals Inc (NASDAQ:EGRX) will report sales of $58.60 million for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for Eagle Pharmaceuticals’ earnings. The lowest sales estimate is $57.30 million and the highest is $59.90 million. Eagle Pharmaceuticals posted sales of $63.02 million in the same quarter last year, which would indicate a negative year-over-year growth rate of 7%. The firm is scheduled to announce its next earnings results on Wednesday, November 14th.
According to Zacks, analysts expect that Eagle Pharmaceuticals will report full-year sales of $227.00 million for the current fiscal year, with estimates ranging from $225.90 million to $228.10 million. For the next financial year, analysts expect that the company will report sales of $259.80 million per share, with estimates ranging from $243.90 million to $275.70 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side analysts that follow Eagle Pharmaceuticals.
Eagle Pharmaceuticals (NASDAQ:EGRX) last announced its earnings results on Tuesday, August 7th. The specialty pharmaceutical company reported $0.95 EPS for the quarter, topping the consensus estimate of $0.80 by $0.15. The business had revenue of $59.30 million for the quarter, compared to the consensus estimate of $51.78 million. Eagle Pharmaceuticals had a return on equity of 19.71% and a net margin of 13.81%.
EGRX has been the topic of several recent analyst reports. TheStreet raised Eagle Pharmaceuticals from a “c” rating to a “b-” rating in a report on Thursday, August 9th. Royal Bank of Canada set a $84.00 price objective on Eagle Pharmaceuticals and gave the stock a “buy” rating in a report on Wednesday, August 8th. Piper Jaffray Companies set a $88.00 price objective on Eagle Pharmaceuticals and gave the stock a “buy” rating in a report on Tuesday, August 7th. Cantor Fitzgerald set a $81.00 price objective on Eagle Pharmaceuticals and gave the stock a “buy” rating in a report on Tuesday, August 7th. Finally, BidaskClub downgraded Eagle Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Wednesday, July 25th. One analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $86.67.
A number of large investors have recently bought and sold shares of EGRX. Wells Fargo & Company MN lifted its holdings in Eagle Pharmaceuticals by 14.4% during the 1st quarter. Wells Fargo & Company MN now owns 23,287 shares of the specialty pharmaceutical company’s stock worth $1,228,000 after buying an additional 2,936 shares in the last quarter. SG Americas Securities LLC lifted its holdings in Eagle Pharmaceuticals by 49.4% during the 1st quarter. SG Americas Securities LLC now owns 11,035 shares of the specialty pharmaceutical company’s stock worth $581,000 after buying an additional 3,650 shares in the last quarter. Mackay Shields LLC acquired a new position in Eagle Pharmaceuticals during the 1st quarter worth $336,000. Virginia Retirement Systems ET AL acquired a new position in Eagle Pharmaceuticals during the 1st quarter worth $632,000. Finally, Schwab Charles Investment Management Inc. lifted its holdings in Eagle Pharmaceuticals by 29.9% during the 1st quarter. Schwab Charles Investment Management Inc. now owns 87,125 shares of the specialty pharmaceutical company’s stock worth $4,591,000 after buying an additional 20,031 shares in the last quarter.
Shares of EGRX opened at $66.66 on Friday. The company has a market capitalization of $1.01 billion, a PE ratio of 29.78 and a beta of 1.31. The company has a debt-to-equity ratio of 0.22, a quick ratio of 4.09 and a current ratio of 4.22. Eagle Pharmaceuticals has a one year low of $48.84 and a one year high of $85.66.
About Eagle Pharmaceuticals
Eagle Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company offers argatroban for heparin-induced thrombocytopenia; Ryanodex for malignant hyperthermia; non-alcohol docetaxel injection, a chemotherapeutic agent for breast, non-small cell lung, prostate, head, and neck cancers/gastric adenocarcinoma; and Bendeka for chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin's lymphoma (NHL).
Read More: Price to Earnings Ratio (PE)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Eagle Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.